Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management.

Literature DB >> 30347029

Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management.

Russell M Levine¹, Ian W Tattersall², Paul A Gaudio^3,4, Brett A King².

Abstract

Mesh：

Substances：

Year: 2018 PMID： 30347029 DOI： 10.1001/jamadermatol.2018.3427

Source DB: PubMed Journal: JAMA Dermatol ISSN： 2168-6068 Impact factor: 10.282

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. Dupilumab-associated ulcerative keratitis.

Authors: Matthew M Wilson; Philipp K Roberts; Mark Daniell
Journal: Int J Ophthalmol Date: 2022-06-18 Impact factor: 1.645

2. Dupilumab-Associated Blepharoconjunctivitis with Giant Papillae.

Authors: Filippos Vingopoulos; Douglas R Lazzaro
Journal: Int Med Case Rep J Date: 2020-07-28

3. Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis.

Authors: Adrien Maudinet; Sandrine Law-Koune; Claire Duretz; Audrey Lasek; Philippe Modiano; Thi Ha Chau Tran
Journal: Ophthalmol Ther Date: 2019-06-22

Review 4. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.

Authors: Gaurav Agnihotri; Katherine Shi; Peter A Lio
Journal: Drugs R D Date: 2019-12

5. Conjunctivitis in dupilumab clinical trials.

Authors: B Akinlade; E Guttman-Yassky; M de Bruin-Weller; E L Simpson; A Blauvelt; M J Cork; E Prens; P Asbell; E Akpek; J Corren; C Bachert; I Hirano; J Weyne; A Korotzer; Z Chen; T Hultsch; X Zhu; J D Davis; L Mannent; J D Hamilton; A Teper; H Staudinger; E Rizova; G Pirozzi; N M H Graham; B Shumel; M Ardeleanu; A Wollenberg
Journal: Br J Dermatol Date: 2019-05-07 Impact factor: 9.302

Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management.

1. Dupilumab-associated ulcerative keratitis.

2. Dupilumab-Associated Blepharoconjunctivitis with Giant Papillae.

3. Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis.

Review 4. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.

5. Conjunctivitis in dupilumab clinical trials.

6. Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis.

7. Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis.

8. Dupilumab-associated cicatrizing ocular disease.

9. Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase.

10. Dupilumab-Associated Mucin Deficiency (DAMD).